

Figure 1




Figure 2

BEST AVAILABLE COPY




Figure 3

BEST AVAILABLE COPY




Figure 4

BEST AVAILABLE COPY




Figure 5

**Hematological changes of Irinotecan + MSC in nude mice on day 22  
after initial treatment of Irinotecan (24 h after third dose)**

<u>Treatment</u>	<u>WBC</u>	<u>RBC</u>	<u>HGB</u>	<u>HCT</u>	<u>MCV</u>	<u>MCH</u>	<u>MCHC</u>	<u>PLT</u>
<u>Control</u>	9.4±3.6	8.7±0.9	16.1±1.6	46.1±2.1	53.4±1.0	18.6±0.1	34.5±0.6	1118±415
MSC (0.2)*	10.3±4.5	9.1±0.5	16.8±0.7	49.4±2.4	54.0±1.0	18.4±0.7	34.0±0.7	756±231
Irinotecan (200)**	3.5±0.5	7.8±1.0	13.8±1.9	40.9±4.2	52.8±0.8	17.5±0.3	32.7±0.6	836±201
Irinotecan (200)** + MSC (0.2)*	8.2±3.1	8.5±0.5	15.4±0.7	44.8±1.8	52.8±1.5	18.0±0.5	34.0±0.6	1174±152

Figure 6




Figure 7A




Figure 7B




Figure 8




Figure 9




Figure 10

Figure 11

# **Hematological changes induced by Oxaliplatin $\pm$ MSC in nude mice on day 5 after Oxaliplatin treatment**

Treatment	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLT
Control	2.69 $\pm$ 1.6	8.75 $\pm$ 0.9	14.9 $\pm$ 1.4	46.7 $\pm$ 4.1	53.3 $\pm$ 0.9	17.1 $\pm$ 0.4	32.0 $\pm$ 0.2	972 $\pm$ 166
MSC(0.2)*	3.45 $\pm$ 2.4	8.30 $\pm$ 0.8	14.0 $\pm$ 1.4	44.8 $\pm$ 4.2	54.0 $\pm$ 1.2	16.8 $\pm$ 0.4	31.2 $\pm$ 0.5	1305 $\pm$ 233
Oxaliplatin(15)**	0.90 $\pm$ 0.8	7.49 $\pm$ 0.6	12.7 $\pm$ 0.9	39.5 $\pm$ 3.0	52.8 $\pm$ 0.9	17.0 $\pm$ 0.4	32.3 $\pm$ 0.8	605 $\pm$ 75
MSC(0.2)* + Oxaliplatin(15)**	2.91 $\pm$ 1.6	7.10 $\pm$ 1.1	12.3 $\pm$ 1.9	38.4 $\pm$ 5.7	54.1 $\pm$ 1.3	17.4 $\pm$ 0.1	32.1 $\pm$ 0.8	922 $\pm$ 214

Figure 12

**White blood cells and platelets changes induced by Oxaliplatin ± MSC in nude mice**

Treatment	White Blood Cells		Neutrophils		Platelets	
	#(1000/CU MM)	% Control	#(1000/CU MM)	% Control	#(1000/CU MM)	% Control
Control	2.69 ± 1.6	100 %	0.75 ± 0.31	100 %	972 ± 166	100 %
MSC(0.2)	3.45 ± 2.4	128 %	0.97 ± 0.30	129 %	1305 ± 233	134 %
Oxaliplatin(15)	0.90 ± 0.8	33 %	0.19 ± 0.10	25 %	605 ± 75	62 %
MSC(0.2) + Oxaliplatin(15)	2.91 ± 1.6	108 %	0.85 ± 0.50	113 %	922 ± 214	95 %

Figure 13

**Differential WBC counts (%) in nude mice on day 5 after Oxaliplatin ± MSC treatment**

Treatment	Neutrophils	Lymphocytes	Monocytes	Eosinophils	Basophils	LUC
Control	27.9 ± 11.4	52.5 ± 18.8	0.78 ± 0.31	1.2 ± 0.5	2.90 ± 1.3	15.2 ± 19.1
MSC(0.2)	28.2 ± 8.7	64.1 ± 4.9	0.40 ± 0.29	1.1 ± 0.5	0.98 ± 0.4	5.2 ± 6.9
Oxaliplatin (15)	21.4 ± 11.0	65.0 ± 12.8	0.46 ± 0.54	1.4 ± 2.3	1.60 ± 1.3	9.9 ± 9.0
MSC (0.2) + Oxaliplatin (15)	29.2 ± 17.4	48.2 ± 6.1	1.94 ± 1.84	1.1 ± 0.5	2.10 ± 1.7	19.4 ± 17.2